The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2018
At a glance
- Drugs PEPIDH1M (Primary)
- Indications Glioma; Medulloblastoma
- Focus Adverse reactions
- Acronyms PRiME
- 31 Aug 2018 Biomarkers information updated
- 11 Jun 2018 Status changed from not yet recruiting to recruiting.
- 30 Jan 2018 Planned End Date changed from 1 May 2021 to 1 Jun 2022.